Lee Willis C's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Feb 28, 2022
- Accession no.
- 0001209191-22-013725
- Filed
- Feb 28, 2022
- Trade date
- Feb 22-28, 2022
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market purchases total $31.5K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee Willis CCIK 0001517775 | Director, Officer (Vice Chairman & COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 22, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +500 | $1.42 | +$710 | 256,774 | Direct | |
| Feb 24, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +5,900 | $1.44 | +$8,496 | 262,674 | Direct | |
| Feb 28, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +7,200 | $1.51 | +$10,872 | 269,874 | Direct | |
| Feb 28, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +6,600 | $1.50 | +$9,900 | 234,994 | Indirect | |
| Feb 28, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +900 | $1.65 | +$1,485 | 1,900 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.